{
    "nctId": "NCT00773695",
    "briefTitle": "A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer",
    "officialTitle": "A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadjuvant Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Reference to the Obtained Responses in Patients With Large Primary HER2 Negative Breast Cancers",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Percentage of Participants With Messenger Ribonucleic Acid (mRNA) Markers of Pathological Complete Response, as Assessed by Magnetic Resonance Imaging (MRI)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed, HER2-negative, men or pre- or post-menopausal women with primary operable adenocarcinoma of the breast, greater than or equal to (\\>=) 2.5 centimeters (cm) in size\n* Eastern Cooperative Oncology Group (ECOG)/world health organization (WHO) performance status less than or equal to (\\</=) 2\n* Normal baseline cardiac function (Left Ventricular Ejection Fraction \\[LVEF\\])\n\nExclusion Criteria:\n\n* Stage IV (metastatic) disease\n* Previous treatment for localized breast cancer less than (\\<) 24 months from diagnosis of present breast cancer\n* Other previous or current cancer except for basal cell cancer or in situ cervical cancer\n* Current or recent use of aspirin (greater than \\[\\>\\] 325 milligrams per day)\n* Clinically significant cardiovascular disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}